Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NCT ID: NCT06484868
Last Updated: 2025-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
12 participants
INTERVENTIONAL
2024-02-08
2028-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
NCT05164341
A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity
NCT01180465
Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)
NCT05351164
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
NCT00392925
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
NCT00449202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metreleptin
Metreleptin \[Recombinant-methionyl human Leptin; r-metHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake
Metreleptin
Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metreleptin
Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amryt Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
Lille, , France
Hopital Pitie-Salpetriere
Paris, , France
Hôpital Saint-Antoine
Paris, , France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, , France
Charite-Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
Berlin, , Germany
Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin
Ulm, , Germany
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, , Italy
Universitá degli Studi "Magna Graecia" di Catanzaro
Catanzaro, , Italy
Azienda Ospedaliero Universitaria Maggiore della Carità di Novara
Novara, , Italy
Azienda Ospedaliero Universitaria Pisana - Stabilimento di Cisanello
Pisa, , Italy
A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia
Udine, , Italy
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
Cambridge, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Marie-Christine Vantyghem
Role: primary
Fabrizio Andreelli
Role: primary
Corinne Vigouroux
Role: primary
Emmanuel Disse
Role: primary
Thomas Bobbert
Role: primary
Martin Wabitsch
Role: primary
Alessandra Gambineri
Role: primary
Antonio Aversa
Role: primary
Flavia Prodam
Role: primary
Giovanni Ceccarini
Role: primary
Annalisa Sechi
Role: primary
Anna Stears
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-502950-14-00
Identifier Type: CTIS
Identifier Source: secondary_id
APL-22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.